By Billy Candra 
In the complex landscape of oncology, a groundbreaking study from the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center (MSK) has provided a definitive explanation for a long-standing paradox in colorectal cancer (CRC). For years, researchers have observed that while a high presence of regulatory T (Treg) cells typically correlates with worse outcomes in most solid tumors, acting as a brake on the body’s natural immune response against cancer, colorectal cancer defied this pattern. In a perplexing exception, tumors rich in Treg cells were often associated with improved survival for patients. This new research, published in the prestigious scientific journal Immunity, resolves this enigma by revealing that not all Treg cells are created equal, particularly within the colorectal tumor microenvironment. The findings suggest a transformative shift in immunotherapy strategies, especially for the most common forms of CRC that have historically proven resistant to such treatments, and potentially for other cancers affecting barrier tissues like the skin, mouth, throat, and stomach.
The Enigma of Colorectal Cancer and Treg Cells
Regulatory T cells, or Tregs, are a specialized subset of T lymphocytes crucial for maintaining immune tolerance. Discovered in the mid-1990s, these cells play a vital role in preventing autoimmune diseases by suppressing excessive immune responses and distinguishing between harmful pathogens and the body’s own healthy tissues. However, in the context of cancer, their suppressive function often becomes a liability. By dampening the anti-tumor immune response, Tregs can inadvertently protect cancer cells from being eradicated by other immune effector cells, such as cytotoxic CD8+ T cells. This general understanding has led to therapeutic strategies aimed at depleting or inhibiting Tregs in many cancers to unleash the immune system’s full potential against malignancies.
Yet, colorectal cancer presented a perplexing deviation from this established paradigm. Epidemiological and observational studies consistently showed that patients with a higher infiltration of Treg cells within their colorectal tumors often experienced better prognoses and longer survival rates. This contradictory evidence left oncologists and immunologists puzzled, hindering the development of targeted therapies based on Treg modulation for CRC. Understanding this anomaly was paramount, as CRC remains the second leading cause of cancer-related death when accounting for both men and women, according to the American Cancer Society, claiming hundreds of thousands of lives globally each year. The vast majority of these cases, approximately 80% to 85%, fall into the category of microsatellite stable (MSS) colorectal cancer with proficient mismatch repair (MMRp), a type notoriously unresponsive to current checkpoint inhibitor immunotherapies. This highlights an urgent need for novel therapeutic approaches.
A Decades-Long Scientific Journey Unravels the Mystery
The breakthrough achieved by the MSK team is not an isolated discovery but the culmination of more than two decades of dedicated research by Dr. Alexander Rudensky, co-senior author of the study and Chair of the Immunology Program at MSK. Dr. Rudensky is widely recognized as one of the world’s foremost authorities on regulatory T cells, having played a pivotal role in establishing their critical function in maintaining immune tolerance. His foundational work illuminated how Treg cells are generated, how they exert their suppressive effects, and their broader influence on the development and progression of various diseases, including cancer. This extensive background provided the essential framework for the current investigation into the nuances of Treg cell behavior within the unique microenvironment of colorectal tumors.
Building upon this deep understanding, the current study was spearheaded by a collaborative team of first authors: Dr. Xiao Huang, a postdoctoral researcher in the Rudensky Lab; Dr. Dan Feng, a former MSK Medical Oncology fellow now at the Icahn School of Medicine at Mount Sinai; and Dr. Sneha Mitra, a postdoctoral researcher in the lab of computational biologist Dr. Christina Leslie, the study’s other senior author. Their combined expertise in immunology, oncology, and computational biology proved instrumental in dissecting the complex cellular interactions at play.
Unveiling the Dual Nature: Two Types of Treg Cells with Opposing Effects
The central revelation of the MSK study is that the seemingly contradictory role of Treg cells in colorectal cancer stems from their heterogeneity. The research team discovered that tumor-associated Treg cells are not a monolithic population but rather comprise two distinct subtypes with diametrically opposing effects on tumor growth. "Instead of the regulatory T cells promoting tumor growth, as they do in most cancers, in colorectal cancer we discovered there are actually two distinct subtypes of Treg cells that play opposing roles — one restrains tumor growth, while the other fuels it," explains Dr. Alexander Rudensky. "It’s these beneficial Treg cells that make the difference, and this underscores the need for selective approaches."
To unravel these distinct roles, the researchers employed a sophisticated mouse model developed at MSK that closely recapitulates the genetic alterations, behavioral characteristics, and immune microenvironment observed in human colorectal tumors. Through a series of meticulously designed experiments, they identified two primary groups of tumor-associated Treg cells: those that produce the signaling molecule interleukin-10 (IL-10), and those that do not.
The IL-10-positive Treg cells emerged as the "beneficial" subtype. These cells actively help slow tumor growth by reducing the activity of Th17 cells, another type of immune cell known to produce interleukin-17 (IL-17). IL-17 functions as a growth signal, promoting the proliferation of tumor cells. By dampening IL-17 production, IL-10-positive Tregs effectively suppress tumor expansion. Interestingly, these protective Treg cells were found to be more prevalent in the healthy tissue surrounding the tumor rather than deep within the tumor mass itself. Crucially, when the researchers selectively removed these IL-10-positive Treg cells in their mouse models, tumors grew more rapidly, confirming their protective role.
Conversely, the IL-10-negative Treg cells were identified as the "harmful" subtype. These cells exert their detrimental effect by actively suppressing powerful immune defenders, particularly CD8+ T cells, which are renowned for their direct cancer-killing capabilities. Unlike their beneficial counterparts, these harmful IL-10-negative Tregs were predominantly located within the tumor microenvironment. The experimental elimination of these IL-10-negative Treg cells led to a significant reduction in tumor size, underscoring their role in promoting tumor progression by neutralizing the body’s anti-cancer immune response.
Validating the Discovery: Human Patient Data Confirms the Findings
The robustness of these findings was further strengthened by their validation in human colorectal cancer samples. The research team analyzed tumor biopsies from patients, confirming the presence of these two distinct populations of IL-10-positive and IL-10-negative Treg cells. This direct evidence from human tissues provided critical support for the biological relevance of the mouse model observations.
To assess the clinical impact of these Treg subtypes, the team analyzed outcomes for over 100 colorectal cancer patients. The results were striking: patients whose tumors exhibited higher levels of the beneficial IL-10-positive Treg cells experienced significantly longer survival. Conversely, patients whose tumors contained a greater proportion of the harmful IL-10-negative Treg cells had poorer outcomes. These correlative clinical data definitively linked the presence and balance of these Treg subtypes to patient prognosis, thereby explaining the long-standing paradox. "This research shows how important these positive cells are," Dr. Huang notes. "And it highlights the need to develop therapies that can selectively eliminate the harmful Tregs while preserving the helpful ones."
Targeting the Achilles’ Heel: CCR8 as a New Therapeutic Strategy
The implications of this discovery are profound, particularly for the development of new immunotherapies. The research identified a key distinguishing feature of the harmful IL-10-negative Treg cells: they express high levels of a protein called CCR8. This cell surface receptor makes them a prime target for selective therapeutic intervention. Critically, these CCR8-expressing, immune-suppressive cells are primarily found within the tumor itself, making them an accessible and specific target for anti-cancer treatments.
This insight builds upon earlier foundational work from Dr. Rudensky’s lab, led by breast cancer surgeon Dr. George Plitas. That research had previously demonstrated that CCR8 is also highly expressed on tumor-infiltrating Treg cells in breast cancer and numerous other human malignancies. This prior discovery laid the groundwork for the idea that antibodies could be engineered to selectively target and deplete these harmful CCR8-positive Treg cells. The rationale is compelling: by eliminating only the Tregs that actively suppress the anti-tumor immune response, the immune system could be unleashed to attack the cancer more effectively, while leaving the beneficial, immune-regulatory Tregs intact, thus minimizing potential autoimmune side effects.
"This idea of using CCR8-depleting antibodies, which was pioneered at MSK, is the main target of global efforts to bring regulatory T cell-based immunotherapy to the clinic," states Dr. Rudensky, who is also a Howard Hughes Medical Institute Investigator. The scientific community has rapidly recognized the potential of this approach, leading to the initiation of multiple clinical trials. These trials, conducted at MSK and other leading institutions worldwide, are evaluating CCR8-targeting antibodies both as standalone therapies and in combination with existing immunotherapies, such as checkpoint inhibitors. The new study on colorectal cancer significantly strengthens the scientific rationale for pursuing this strategy, not only for CRC but potentially for a broader spectrum of cancers.
Beyond Colorectal Cancer: Broader Implications for Barrier Tissues
The MSK team’s investigation extended beyond colorectal cancer to explore whether similar immune patterns exist in other tumor types. By analyzing a large dataset of T cells from 16 different cancers, they indeed found comparable divisions between IL-10-positive and IL-10-negative Treg cells in several cancers affecting barrier tissues, including those of the skin and the lining of the mouth, throat, and stomach.
"What these tissues have in common is that immune cells play a critical role in constantly defending and repairing them as they’re exposed to microbes and environmental stresses," explains Dr. Mitra, who led the data analysis. This observation suggests a conserved immunological mechanism across these barrier tissues, where a delicate balance of immune regulation is essential for maintaining health and responding to threats. Consequently, therapies designed to selectively remove the harmful IL-10-negative Treg cells in colorectal cancer might also prove effective against these other barrier tissue cancers, significantly expanding the potential reach of this novel immunotherapy approach. This broad applicability represents a significant leap forward in precision oncology, moving towards treatments tailored to specific immune cell subsets rather than broad-spectrum immune modulation.
The Challenge of Metastatic Disease: A Different Immune Landscape
While the findings offer immense promise for primary colorectal tumors, the researchers also highlighted the critical importance of disease stage. When studying colorectal cancer that had metastasized to the liver, a common site for CRC spread, they observed a notably different immune pattern. In these metastatic tumors, the harmful IL-10-negative Treg cells significantly outnumbered the beneficial IL-10-positive cells. Furthermore, unlike in primary tumors, the complete removal of all Treg cells in this metastatic context actually caused the tumors to shrink.
This stark difference underscores that the immune microenvironment can evolve and vary dramatically depending on the tumor’s location and stage. Metastatic lesions often present a more profoundly immunosuppressive environment, where the balance has shifted overwhelmingly towards pro-tumorigenic immune cells. This finding emphasizes the need for highly adaptive and context-dependent treatment strategies, suggesting that therapies effective for primary tumors may need to be modified or combined differently for advanced, metastatic disease. It calls for further research to precisely characterize the immune landscape of different metastatic sites and stages to optimize therapeutic interventions.
The Future of Immunotherapy for Colorectal Cancer
The study by the Sloan Kettering Institute marks a pivotal moment in cancer immunology. By dissecting the heterogeneity of regulatory T cells, the researchers have not only resolved a long-standing paradox in colorectal cancer but have also unveiled a clear path forward for developing more effective and targeted immunotherapies. For the vast majority of CRC patients with MSS tumors, who currently have limited immunotherapy options, the selective targeting of CCR8-expressing, harmful Treg cells represents a beacon of hope. This approach promises to unleash the body’s inherent anti-cancer immunity without compromising essential immune tolerance mechanisms.
As clinical trials for CCR8-depleting antibodies advance, the scientific community and patient advocacy groups await their results with great anticipation. The ability to precisely modulate the immune response, preserving beneficial immune components while eliminating detrimental ones, is the holy grail of modern immunotherapy. This research, rooted in decades of fundamental immunological discovery, brings that vision closer to reality, offering a tangible strategy to improve outcomes for millions affected by colorectal cancer and potentially a range of other challenging malignancies. The future of cancer treatment will increasingly rely on such nuanced understandings of the tumor microenvironment, paving the way for truly personalized and effective therapies.
Authors, Funding, and Disclosures
Additional authors on this impactful study include Emma Andretta, Nima Hooshdaran, Aazam Ghelani, Eric Wang, Joe Frost, Victoria Lawless, Aparna Vancheswaran, Qingwen Jiang, Cheryl Mai, and Karuna Ganesh.
Key institutional support was provided by the Integrated Genomics Operation and the Single Cell Research Initiative at MSK, which played crucial roles in the sophisticated analytical aspects of the research.
The comprehensive funding for this groundbreaking work was generously provided by several prominent organizations, including the National Cancer Institute (P30 CA008748, U54 CA274492, T32 CA009512), the National Institute of Allergy and Infectious Diseases (AI034206), the Ludwig Center for Cancer Immunotherapy at MSK, the Howard Hughes Medical Institute, the Cancer Research Institute, and a Marie-Josée Kravis Fellowship in Quantitative Biology.
Dr. Rudensky, a leading figure in the field, has disclosed various affiliations. He serves on scientific advisory boards and holds equity in Sonoma Biotherapeutics, RAPT Therapeutics, Coherus Oncology, Santa Ana Bio, Odyssey Therapeutics, and Nilo Therapeutics. Additionally, he is a scientific advisory board member for Amgen, BioInvent, and Vedanta Biosciences, has provided consultation services for AbbVie, and contributes as an editor of the Journal of Experimental Medicine and an editorial advisor to Immunity. Dr. Rudensky and Dr. Plitas are also recognized as inventors on patents and patent applications held by MSK, which are related to CCR8-based therapeutic depletion of tumoral Treg cells and the development of novel antibodies targeting CCR8. These disclosures underscore the potential translational impact of their pioneering research.
